Optimizing autologous blood donation by recombinant human erythropoietin (rhu-EPO) and interleukin 3 (IL-3).
The transfusion of autologous blood protects surgical patients from both the transfusion transmitted diseases (AIDS, posttransfusion hepatitis) and the immunosuppressive effects of homologous blood. Nevertheless, the use of autologous blood is still unsatisfactory, mainly because of the elaborated logistics, organization and technique required and the often insufficient amounts of autologous blood gained. Today, the major growth-factors of erythropoiesis are available as recombinant analogues. In the studies reviewed here, we investigated the effects of rhu-EPO and IL-3 on perioperative erythropoiesis in two canine models of acute isovolemic hemodilution. Different therapeutic concepts are compared with respect to preoperative changes in hematocrit, the volume of autologous blood gained and the duration of postdilutional anemia.
Krieter
H
H
Department of Experimental Surgery, University of Heidelberg, Germany.
Frey
L
L
Segiet
W
W
Brückner
U B
UB
Krumwieh
D
D
Seiler
F R
FR
Messmer
K
K
D000818:Animals; D001804:Blood Transfusion, Autologous; D004285:Dogs; D004334:Drug Administration Schedule; D004906:Erythrocyte Count / Q000187:drug effects; D004920:Erythropoiesis / Q000187:drug effects*; D004921:Erythropoietin / Q000008:administration & dosage / Q000494:pharmacology*; D005260:Female; D006400:Hematocrit; D006438:Hemodilution; D006454:Hemoglobins / Q000378:metabolism; D007377:Interleukin-3 / Q000008:administration & dosage / Q000494:pharmacology*; D007958:Leukocyte Count / Q000187:drug effects; D008297:Male; D010976:Platelet Count / Q000187:drug effects; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000494:pharmacology*; D012156:Reticulocytes / Q000166:cytology / Q000187:drug effects
D006454:Hemoglobins; D007377:Interleukin-3; D011994:Recombinant Proteins; D004921:Erythropoietin